Hiroshi Yatsuhashi

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Masashi Mizokami, Osamu Yokosuka, Tetsuo Takehara et al. · The Lancet Infectious Diseases · 2015 · 362 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Minoru Nakamura, Hisayoshi Kondo, Tsuyoshi Mori et al. · Hepatology · 2006 · 361 citations · Full text

Medicine, Hematology, Immunology +13

Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population

Minoru Nakamura, Nao Nishida, Minae Kawashima et al. · The American Journal of Human Genetics · 2012 · 271 citations · Full text

Life Sciences, Genetics, Molecular Genetics +12

A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update

Ryosuke Tateishi, Koji Uchino, Naoto Fujiwara et al. · Journal of Gastroenterology · 2018 · 238 citations · Full text

Medicine, Oncology, Cancer Epidemiology +10